Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

By Daniella Parra Promontory Therapeutics said its Phase 2 meeting with the FDA cleared the way to launch a Phase 3 registrational trial of PT-112 monotherapy for metastatic castration-resistant ...

Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, ...

Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the upcoming European Society for Medical Oncology (ESMO) ...

This can include photothermal or photodynamic effects, which either directly eliminate cancer cells or trigger immunogenic ...

The study also found that blocking nitrosylation triggered immunogenic cell death, a process that causes tumor cells to release distress signals. These signals attracted immune cells such as CD8 ...

It works through a combination of mechanisms: it induces immunogenic cell death via reactive oxygen species and copper-triggered cuproptosis—a newly recognized form of regulated cell death.

More information: Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage, Nature Cell Biology ...

The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635 ...